Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27660874 | 0.83 | TSHR (0.36) | CYP1A2 | |
| SCHEMBL29280364 | 0.82 | SKP2 (0.39) | — | |
| SCHEMBL458330 | 0.82 | PTGS2 (0.42) | NOS3NOS1NOS2TRPA1PTGS2 | |
| SCHEMBL15352533 | 0.78 | PTPN1 (0.31) | — | |
| SCHEMBL11513183 | 0.78 | NQO1 (0.36) | NQO1CYP1A2POLBTP53 | |
| SCHEMBL128388 | 0.78 | NQO1 (0.46) | NQO1CYP1A2TP53 | |
| SCHEMBL15353293 | 0.77 | TRPA1 (0.31) | TRPA1PTGS2CYP1A2CYP2A6 | |
| SCHEMBL4751852 | 0.77 | ALDH1A1 (0.44) | CYP1A2TP53HTR2AHTR2B | |
| SCHEMBL14639020 | 0.77 | THRB (0.36) | CYP1A2 | |
| SCHEMBL15352630 | 0.76 | NQO1 (0.34) | NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-10077254-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-09-18 | — | — | US | disclosed |
| EP-3059233-B1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | SUMITOMO CHEMICAL CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9565856-B2 | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20160272622-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3059233-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | Sumitomo Chemical Company, Limited (JP) | 2016-08-24 | — | — | EP | disclosed |
| EP-2841429-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| WO-2013162072-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| WO-2002072559-A1 | PROCESS TO INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-1115700-A1 | OPTICALLY ACTIVE SUBSTITUTED N-ARYL-O-ARYLOXYALKYL-CARBAMATES | BAYER AG (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000017157-A1 | OPTICALLY ACTIVE SUBSTITUTED N-ARYL-O-ARYLOXYALKYL-CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
| US-4820821-A | ANTIDEPRESSANTS, ANTIHYPOTONIC AGENTS, ANTIPARKINSON DRUGS | BASF AKTIENGESELLSCHAFT (DE) | 1989-04-11 | — | — | US | disclosed |
| EP-0227941-A1 | 1-Phenyl-4-(1H)-pyridazinimines, their preparation and use | BASF Aktiengesellschaft (DE) | 1987-07-08 | — | — | EP | disclosed |
| EP-0078989-B1 | PYRIDAZINONE IMINES AND THEIR PHYSIOLOGICALLY TOLERABLE ADDITION SALTS, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL AGENTS CONTAINING THOSE COMPOUNDS | BASF Aktiengesellschaft (DE) | 1985-05-08 | — | — | EP | disclosed |
| EP-0116853-A1 | Pyridazinones, processes for preparing them, therapeutical compositions containing these compounds and their use | BASF Aktiengesellschaft (DE) | 1984-08-29 | — | — | EP | disclosed |
| EP-0042513-B1 | DIHYDROPYRIDAZINONES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | BASF Aktiengesellschaft (DE) | 1984-08-08 | — | — | EP | disclosed |
| US-4415571-A | HYPOTENSIVE AGENTS; THROMBOSIS; ANTICOAGULANTS; CARDIOVASCULAR DISORDDERS | BASF AKTIENGESELLSCHAFT (DE) | 1983-11-15 | — | — | US | disclosed |
| EP-0078989-A1 | Pyridazinone imines and their physiologically tolerable addition salts, process for their preparation and therapeutical agents containing those compounds | BASF Aktiengesellschaft (DE) | 1983-05-18 | — | — | EP | disclosed |
| EP-0042513-A1 | Dihydropyridazinones, processes for their preparation and pharmaceutical compositions containing these compounds | BASF Aktiengesellschaft (DE) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077254-B2 | Tetrazolinone compound and use thereof | MT-CO1, UQCRB, MT-CO2 | NQO1 1274/4885NOS3 1707/4885NOS1 1211/4885 |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | CBR3, CYCS, CBR1 | NQO1 2127/4885NOS3 1810/4885NOS1 2613/4885 |
| US-20160272622-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MT-CO1, UQCRB, MT-CO2 | NQO1 1274/4885NOS3 1707/4885NOS1 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.